Érika Fernandes Campos

Érika Fernandes Campos

Auto-generated profile, based on publicly available information

Érika Fernandes Campos

Transplant Immunology Laboratory, HLAGyn, Goiânia, Goiás, Brazil

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2017 in American Journal of Nephrology
Verified
Journal Article
Closed access
AFAlexandra Ferreira
Alexandra Ferreira
CFClaudia Felipe
Claudia Felipe
MCMarina Pontello Cristelli
Marina Pontello Cristelli
LVLaila Viana
Laila Viana
GBGeovana Basso
Geovana Basso
JPJose Medina Pestana
Jose Medina Pestana
Background: This analysis compared efficacy, renal function, and histology in kidney transplant recipients receiving tacrolimus (TAC) combined with everolimus (EVR) or mycophenolate (MPS). Methods: This was a retrospective analysis from a randomized trial in kidney transplant recipients who received a single 3 mg/kg dose of rabbit antithymocyte globulin (r-ATG), TAC, EVR, and prednisone (PRED; r-ATG/EVR, n = 85), basiliximab (BAS), TAC, EVR, and PRED (BAS/EVR, n = 102) or BAS, TAC, MPS, and PRED (BAS/MPS, n = 101). We evaluated the incidence of de novo donor-specific anti-human leukocyte antigens antibodies (DSA) and histology on protocol biopsies at 12 months, and the incidence of acute rejection, estimated glomerular filtration rate (eGFR) and proteinuria at 36 months. Results: At 12 months, there were no differences in de novo DSA (6.4 vs. 3.4 vs. 5.5%) or in subclinical inflammation (2.0 vs. 4.8 vs. 10.2%), interstitial fibrosis/tubular atrophy (57.1 vs. 58.5 vs. 53.8%) and C4d deposition (2.0 vs. 7.3 vs. 2.6%). At 36 months, there were no differences in the incidence of treatment failure (19.0 vs. 27.7 vs. 27.7%, p = 0.186), first biopsy-proven acute rejection (9.5 vs. 21.8 vs. 16.8%, p = 0.073), and urine protein/creatinine ratios (0.53 ± 1.05 vs. 0.62 ± 0.75 vs. 0.71 ± 1.24). eGFR was lower in the BAS/EVR compared to that in the BAS/MPS group (53.4 ± 20.9 vs. 50.8 ± 19.5 vs. 60.7 ± 21.2 mL/min/1.73 m2, p = 0.017) but comparable using a sensitive analysis (49.5 ± 23 vs. 47.5 ± 22.6 vs. 53.6 ± 27.8 mL/min/1.73 m2, p = 0.207). Conclusion: In this cohort, the use of EVR and reduced TAC concentrations were associated with comparable efficacy, renal function, and histological parameters compared to the standard-of-care immunosuppressive regimen.

3 July 2018 in Transplant International
Verified
Journal Article
Closed access
PDF file
TSTainá Veras de Sandes-Freitas
Tainá Veras de Sandes-Freitas
PPPetrucia Maria Antero Pinheiro
Petrucia Maria Antero Pinheiro
MSMaria Luíza de Mattos Brito Oliveira Sales
Maria Luíza de Mattos Brito Oliveira Sales
CGCeli Melo Girão
Celi Melo Girão
ÉCÉrika Fernandes Campos
Érika Fernandes Campos
RERonaldo de Matos Esmeraldo
Ronaldo de Matos Esmeraldo
There is no evidence of whether everolimus(EVR) reduces cytomegalovirus(CMV) events in patients receiving steroid‐free regimens.Besides, studies evaluating a tacrolimus(TAC) and EVR regimen are limited to 1‐year follow‐up. In this single‐center prospective randomized trial, the incidence of CMV and 3‐year efficacy and safety outcomes of EVR were compared to those of mycophenolate sodium(MPS) in a steroid‐free regimen based on low‐exposure TAC.Both groups received rabbit anti‐thymocyte globulin(r‐ATG) induction(6mg/kg) and the steroids were withdrawn at day 7. Maintenance immunosuppression consisted of TAC(4–7ng/mL until month 3 and 2–4ng/mL thereafter) plus EVR (3–8ng/mL) in the EVR group (n=59); and TAC (4–7 ng/mL during all follow‐up) plus MPS(1440mg) in the MPS group(n=56).The EVR group presented with a lower incidence of CMV events (18.6 vs. 50%,p=0.001).No differences were observed in biopsy‐proven acute rejection (6.8% vs. 3.6%,p=0.680),graft loss (0.0% vs. 1.8%,p=0.487),death (6.8% vs. 1.8%,p=0.365), or estimated glomerular filtration rate at 36 months (61.1±25.4 vs. 66.3±24mL/min/1.73m2,p=0.369).A higher proportion of patients discontinued MPS treatment (8.5% vs. 26.8%,p=0.013) for safety issues.In conclusion, EVR was associated with lower rates of CMV events in patients induced with standard dose r‐ATG and a maintenance steroid‐free regimen based on TAC.This regimen effectively prevented acute rejection and demonstrated a more favorable safety profile

1 January 2010 in Brazilian Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ÉCÉrika Fernandes Campos
Érika Fernandes Campos
IDIlias Ioannis Nikolaos Doxiadis
Ilias Ioannis Nikolaos Doxiadis
JTJulia Temin
Julia Temin
APAndrea Plothow
Andrea Plothow
EBElaine Cristina Bellintani
Elaine Cristina Bellintani
MGMaria Gerbase-DeLima
Maria Gerbase-DeLima
Objetivo: O acúmulo de pacientes hipersensibilizados nas listas de espera de transplante renal é um problema universal e achar doadores para os mesmos representa um grande desafio para organizações de distribuição de órgãos. O objetivo deste trabalho é descrever uma possível versão brasileira do programa “Eurotransplant Acceptable Mismatch” e relatar os resultados de um estudo realizado para testar sua eficiência. Método: As incompatibilidades aceitáveis foram definidas pelo teste Luminex com esferas recobertas por um único antígeno, sendo cada teste interpretado individualmente, com o auxílio do algoritmo “HLAMatchmaker”. A predição de prova cruzada negativa foi validada em 86 provas cruzadas negativas T, utilizando o método de citotoxicidade dependente de complemento sensibilizado com anti- globulina humana. Resultados: A estimativa das chances de 40 pacientes hipersensibilizados encontrarem um doador através do programa mostrou que para aproximadamente 70% dos mesmos haveria oferta de rim com compatibilidade no sistema ABO, sem incompatibilidades HLA-DR e provas cruzadas T e B negativas, dentro de um período de dois anos após a entrada no programa. Por outro lado, para cerca de 30% dos pacientes, as chances de encontrar um doador seriam mínimas, mesmo dentro de períodos de três a cinco anos. Conclusões. Nós estimamos que em torno de 70% dos pacientes hipersensibilizados claramente beneficiar-se-iam do algoritmo proposto neste estudo. Por outro lado, os pacientes para os quais o achado de um doador fosse altamente improvável seriam candidatos a protocolos de dessensibização/ redução de anticorpos. Concluímos que a informação a respeito da transplantabilidade de cada paciente fornecida pelo algoritmo aqui descrito é uma ferramenta poderosa para um adequado manejo de pacientes altamente sensibilizados em programas regionais nacionais e internacionais de distribuição de órgãos de doadores falecidos.